|
Jul 2
|
What's Fueling Tempus AI's Explosive Sales Growth?
|
|
Jul 1
|
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
|
|
Jun 30
|
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
|
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
|
Jun 27
|
Will Strong Asceniv Sales Drive ADMA Biologics Further?
|
|
Jun 4
|
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
|
|
May 27
|
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent
|
|
May 27
|
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
|
|
May 20
|
Takeda Taps Salesforce (CRM) for AI-Driven Customer Experience Platform
|
|
Mar 14
|
TAK or DSNKY: Which Is the Better Value Stock Right Now?
|
|
Mar 13
|
Takeda’s $770M deal deepens Big Pharma’s omics push
|
|
Feb 24
|
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
|
|
Feb 17
|
TAK vs. DSNKY: Which Stock Is the Better Value Option?
|
|
Feb 15
|
Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
|
|
Feb 14
|
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
|
|
Feb 12
|
BBI announces $31m facility for Shire to enhance asset finance
|
|
Feb 10
|
Are orexins the next golden child of neuroscience?
|